WEBULL
WebtradeDownload

SofWave Medical (TASE:SOFW) Stock Sees Profit Strength Meet Premium Valuation

Simply Wall St · 2d ago

SofWave Medical went into this earnings print with a bruised share price, down over the past week, month and quarter, and a premium P/E near 52x that already asked a lot from the story. The market closed yesterday with the stock at ₪38.5. The headline from Q2 is simple: the company is now putting real profits behind that rich multiple.

Revenue for the quarter came in at US$29.961 million and basic earnings per share were US$0.06932. Both figures point to a business that is now consistently generating earnings from its aesthetic medical equipment franchise.

Like that SofWave Medical is now putting earnings behind a rich P/E multiple, but want a wider set of profitable growth ideas to benchmark it against? Check out our hand picked list of 548 high quality undiscovered gems.

Q2 2026 Earnings Summary

  • Revenue Q2 2026 vs. Q2 2025: US$29.961 million vs. US$20.99 million (higher in the latest quarter)
  • Net Income Q2 2026 vs. Q2 2025: US$2.511 million vs. US$1.517 million (higher profit in the latest quarter)
  • Basic EPS Q2 2026 vs. Q2 2025: US$0.06932 vs. US$0.042981 (higher earnings per share in the latest quarter)
  • Trailing 12 Month Revenue to Q2 2026 vs. TTM to Q2 2025: US$104.345 million vs. US$69.486 million (higher revenue over the trailing year)

Prefer clean charts instead of another dense earnings recap? See SofWave Medical's full financial picture with a visual breakdown of its valuation in the company report for SofWave Medical.

TASE:SOFW Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
TASE:SOFW Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Profitable SofWave growth supports the upbeat story

The latest quarter gives SofWave Medical investors some concrete support for a more optimistic view. Revenue of US$29.961 million and net income of US$2.511 million both run ahead of the prior year period. Earnings per share also moved higher. The trailing 12 month revenue line now sits at US$104.345 million, which is above the prior trailing period. For a company leaning on a global non invasive aesthetic platform pitch, investors now see a business that is producing earnings and scaling its top line at the same time.

Share price weakness keeps the cautious view alive

The bear case is not invalidated. SofWave Medical has reported higher revenue, profit and earnings per share, yet the stock is down about 2% over 7 days, 10% over 30 days and 19% over 90 days to ₪38.5 as of early August 2026. That gap between improving financials and softer trading can reflect concerns about competition in aesthetic devices or questions about the durability of current growth trends.

With SofWave Medical now profitable, yet trading on a 52.3x P/E and showing a large gap to the supplied DCF value, check the real balance sheet strength and cash runway math in our financial health analysis of SofWave Medical stock.

Stay Ahead With Simply Wall St

If SofWave Medical's shift to consistent profitability with a premium P/E and recent share price weakness has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and wait for an entry point that suits you. After you decide to take a position, keep your next moves focused with the Portfolio Command Center that highlights only the key developments that matter for your holdings. For a longer term view, compare your thinking with other investors through the Community and see how sentiment and thesis quality evolve over time. This way you can spot potential catalysts or emerging risks early and stay a step ahead of the wider market.

Seeking Alternatives Beyond SofWave Medical?

Some stocks are already building quiet breakout momentum while others are still flying under the radar for now. Do not get caught reacting late. Act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.